Drug-like analogues of the parasitic worm-derived immunomodulator ES-62 are therapeutic in the MRL/Lpr model of systemic lupus erythematosus

The Parasitic Worm Product ES-62 Targets Myeloid Differentiation Factor 88-Dependent Effector Mechanisms to Suppress Antinuclear Antibody Production and Proteinuria in MRL/lprMice

(2015) David T. Rodgers et al.   Arthritis & Rheumatology

Signaling through the Adaptor Molecule MyD88 in CD4+ T Cells Is Required to Overcome Suppression by Regulatory T Cells

(2014) Dominik Schenten et al.   IMMUNITY

MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases

(2014) Minjia Yu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Mediators of Inflammation and Their Effect on Resident Renal Cells: Implications in Lupus Nephritis

(2013) Susan Yung et al.   Clinical & Developmental Immunology

Signals via the Adaptor MyD88 in B Cells and DCs Make Distinct and Synergistic Contributions to Immune Activation and Tissue Damage in Lupus

(2013) Lino L. Teichmann et al.   IMMUNITY

Requirement for MyD88 Signaling in B Cells and Dendritic Cells for Germinal Center Anti-Nuclear Antibody Production in Lyn-Deficient Mice

(2013) Z. Hua et al.   JOURNAL OF IMMUNOLOGY

Designing Anti-inflammatory Drugs from Parasitic Worms: A Synthetic Small Molecule Analogue of the Acanthocheilonema viteae Product ES-62 Prevents Development of Collagen-Induced Arthritis

(2013) Lamyaa Al-Riyami et al.   JOURNAL OF MEDICINAL CHEMISTRY

Future prospects in biologic therapy for systemic lupus erythematosus

(2013) William Stohl   Nature Reviews Rheumatology

Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases

(2013) Jing Li et al.   PHARMACOLOGY & THERAPEUTICS

The parasitic helminth product ES-62 suppresses pathogenesis in collagen-induced arthritis by targeting the interleukin-17-producing cellular network at multiple sites

(2012) Miguel A. Pineda et al.   ARTHRITIS AND RHEUMATISM

The worm returns

(2012) Joel V. Weinstock   NATURE

Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients

(2010) Federica Capolunghi et al.   RHEUMATOLOGY